title: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
abstract: Therapeutic options for patients with castration-resistant prostate cancer (CRPC) remain limited. In a multicenter, Phase II study, 65 patients with histologically confirmed CRPC received a biomodulatory regimen during the six-month core study. Treatment comprised daily doses of imatinib mesylate, pioglitazone, etoricoxib, treosulfan and dexamethasone. The primary endpoint was prostate-specific antigen (PSA) response. Responders could enter an extension phase until disease progression or intolerable toxicity occurred. Mean PSA was 45.3 ng/mL at baseline, and 77 % of patients had a PSA doubling time <3 months. Of the 61 evaluable patients, 37 patients (60.6 %) responded or had stable disease and 23 of them (37.7 % of 61 patients) were PSA responders. Among the 23 responders mean PSA decreased from 278.9 ± 784.1 ng/mL at baseline to 8.8 ± 11.6 ng/mL at the final visit (week 24). The progression-free survival (PFS) was 467 days in the ITT population. Of the 947 adverse events, 57.6 % were suspected to be drug-related, 13.8 % led to dose adjustment or permanent discontinuation and 40.2 % required concomitant medication. This novel combination approach led to an impressive PSA response rate of 37.7 % in CRPC patients. The good PSA response and PFS rate combined with the manageable toxicity profile suggest an alternative treatment option.
authors.affiliation: Department of Hematology and Oncology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Vogelhuber
authors.forename: S
authors.initials: S
authors.lastname: Feyerabend
authors.forename: A
authors.initials: A
authors.lastname: Stenzl
authors.forename: T
authors.initials: T
authors.lastname: Suedhoff
authors.forename: M
authors.initials: M
authors.lastname: Schulze
authors.forename: J
authors.initials: J
authors.lastname: Huebner
authors.forename: R
authors.initials: R
authors.lastname: Oberneder
authors.forename: W
authors.initials: W
authors.lastname: Wieland
authors.forename: S
authors.initials: S
authors.lastname: Mueller
authors.forename: F
authors.initials: F
authors.lastname: Eichhorn
authors.forename: H
authors.initials: H
authors.lastname: Heinzer
authors.forename: K
authors.initials: K
authors.lastname: Schmidt
authors.forename: M
authors.initials: M
authors.lastname: Baier
authors.forename: A
authors.initials: A
authors.lastname: Ruebel
authors.forename: K
authors.initials: K
authors.lastname: Birkholz
authors.forename: A
authors.initials: A
authors.lastname: Bakhshandeh-Bath
authors.forename: R
authors.initials: R
authors.lastname: Andreesen
authors.forename: W
authors.initials: W
authors.lastname: Herr
authors.forename: A
authors.initials: A
authors.lastname: Reichle